Vaccines
Moderna Says FDA Needs More Time to Assess Vaccine for Teens
- FDA is reviewing international analyses on myocarditis risks
- U.S. cleared Pfizer and BioNTech shot for ages 5 to 11 Friday
This article is for subscribers only.
Sign up here for our daily coronavirus newsletter on what you need to know
Moderna Inc. said it was notified the U.S. Food and Drug Administration will require additional time to assess the company’s emergency request to approve its Covid-19 vaccine for children ages 12 to 17 as regulators examine the risk of a rare heart inflammation.